We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Feng Zhang's latest CRISPR company, Beam Therapeutics, officially came out of stealth Monday with $87 million in series A funding and a mission to develop "precision genetic medicines"